Proton Beam Therapy in the Oligometastatic/Oligorecurrent Setting: Is There a Role? A Literature Review
- Author(s)
- Gaito, S; Marvaso, G; Ortiz, R; Crellin, A; Aznar, MC; Indelicato, DJ; Pan, S; Whitfield, G; Alongi, F; Jereczek-Fossa, BA; Burnet, N; Li, MP; Rothwell, B; Smith, E; Colaco, RJ;
- Details
- Publication Year 2023-04-26,Volume 15,Issue #9,Page 2489
- Journal Title
- Cancers
- Publication Type
- Review
- Abstract
- BACKGROUND: Stereotactic ablative radiotherapy (SABR) and stereotactic radiosurgery (SRS) with conventional photon radiotherapy (XRT) are well-established treatment options for selected patients with oligometastatic/oligorecurrent disease. The use of PBT for SABR-SRS is attractive given the property of a lack of exit dose. The aim of this review is to evaluate the role and current utilisation of PBT in the oligometastatic/oligorecurrent setting. METHODS: Using Medline and Embase, a comprehensive literature review was conducted following the PICO (Patients, Intervention, Comparison, and Outcomes) criteria, which returned 83 records. After screening, 16 records were deemed to be relevant and included in the review. RESULTS: Six of the sixteen records analysed originated in Japan, six in the USA, and four in Europe. The focus was oligometastatic disease in 12, oligorecurrence in 3, and both in 1. Most of the studies analysed (12/16) were retrospective cohorts or case reports, two were phase II clinical trials, one was a literature review, and one study discussed the pros and cons of PBT in these settings. The studies presented in this review included a total of 925 patients. The metastatic sites analysed in these articles were the liver (4/16), lungs (3/16), thoracic lymph nodes (2/16), bone (2/16), brain (1/16), pelvis (1/16), and various sites in 2/16. CONCLUSIONS: PBT could represent an option for the treatment of oligometastatic/oligorecurrent disease in patients with a low metastatic burden. Nevertheless, due to its limited availability, PBT has traditionally been funded for selected tumour indications that are defined as curable. The availability of new systemic therapies has widened this definition. This, together with the exponential growth of PBT capacity worldwide, will potentially redefine its commissioning to include selected patients with oligometastatic/oligorecurrent disease. To date, PBT has been used with encouraging results for the treatment of liver metastases. However, PBT could be an option in those cases in which the reduced radiation exposure to normal tissues leads to a clinically significant reduction in treatment-related toxicities.
- Publisher
- MDPI
- Keywords
- oligometastases; oligorecurrences; proton beam therapy
- Department(s)
- Radiation Oncology
- PubMed ID
- 37173955
- Publisher's Version
- https://doi.org/10.3390/cancers15092489
- Open Access at Publisher's Site
https://doi.org/10.3390/cancers15092489- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-07-25 05:27:31
Last Modified: 2023-07-25 05:28:06